Skip to content
Altius – Lifestyle
Author:
VolitionRx Limited
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
August 26, 2026
Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis
August 26, 2026
Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
August 12, 2026
Volition Advances Nu.Q® NETs Platform Towards Commercialization
July 30, 2026
VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test
July 7, 2026
VolitionRx Announces Collaboration with Sysmex
June 17, 2026